Updates to the Handbook
A list of updates made to the Handbook is provided below by the date they were published. The Handbook will be reviewed 3 times per year following ATAGI meetings in February, May and August. Urgent updates to the content will be made as required.
Recently added
This page was added on 06 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
1 August 2017
The following pages were updated:
Diphtheria
Changes to 4.2.4 Vaccines and 4.2.12 Variations from product information.
4.2.4 Vaccines and 4.2.12 Variations from product information
Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also Chapters, 4.2 Diphtheria, 4.3 Haemophilus influenzae type b, 4.14 Polio and 4.19 Tetanus).
4.2.7 Recommendations
Addition of text clarifying vaccination in laboratory workers.
Haemophilus influenzae type b (Hib)
Changes to 4.3.4 Vaccines, 4.3.7 Recommendations, and 4.3.12 Variations from product information
4.3.4 Vaccines
Addition of text to clarify situations in which vaccine interchangeability will now need to be considered.
4.3.4 Vaccines, 4.3.7 Recommendations, 4.3.12 Variations from product information
Amendment of text due to the discontinuation of the Haemophilus b conjugate (PRP-OMP) vaccine (PedvaxHIB) (Refer also Chapter 2.1 Pre-vaccination).
Amendment of text due to the discontinuation of a vaccine type, Pediacel (Refer also Chapters, 4.2 Diphtheria, 4.12 Pertussis, 4.14 Polio and 4.19 Tetanus).
Hepatitis A
Changes to 4.4.4 Vaccines and 4.4.6 Dosage and administration
4.4.4 Vaccines
Amendment of text to align with new product information.
4.4.6 Dosage and administration
Correction of incorrect text, replacing ELISA units with antigen units and changing 12 months to 36 months.
Measles
Changes to 4.9.4 Vaccines; 4.9.5 Transport, storage and handling; 4.11 Mumps and 4.18 Rubella); 4.9.10 Precautions; and 4.9.11 Adverse events
4.9.4 Vaccines
Correction of text due to incorrect nomenclature (Refer also Chapters, 4.11 Mumps and 4.18 Rubella and 4.22 Varicella).
Updating of text for consistency with new product information. In particular, the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.11 Mumps, 4.18 Rubella, 4.21 Typhoid, 4.22 Varicella and Appendices 3 & 4).
4.9.5 Transport, storage and handling
Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.11 Mumps and 4.18 Rubella).
4.9.10 Precautions, 4.9.11 Adverse events
Moving text on egg allergy from Precautions to Adverse Events to be consistent with other chapters (Refer also Chapters, 4.11 Mumps, 4.18 Rubella and 4.22 Varicella).
4.9.11 Adverse events
Addition of text on ovalbumin quantity in vaccine.
Mumps
Changes to 4.11.4 Vaccines; 4.11.5 Transport, storage and handling; and 4.11.11 Adverse events
4.11.4 Vaccines
Correction of text due to incorrect nomenclature (Refer also Chapters, 4.9 Measles, 4.18 Rubella and 4.22 Varicella).
Updating of text for consistency with new product information. In particular, the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.9 Measles, 4.18 Rubella, 4.21 Typhoid, 4.22 Varicella and Appendices 3 & 4).
4.11.5 Transport, storage and handling
Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.9 Measles and 4.18 Rubella).
4.11.11 Adverse events
Addition of text on egg allergy to Adverse Events to be consistent with other chapters. (Refer also Chapters, 4.9 Measles, 4.18 Rubella and 4.22 Varicella).
Pertussis (whooping cough)
Changes to 4.12.4 Vaccines and 4.12.12 Variations from product information.
4.12.4 Vaccines and 4.12.12 Variations from product information
Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also Chapters, 4.2 Diphtheria, 4.3 Haemophilus influenzae type b, 4.14 Polio and 4.19 Tetanus).
Poliomyelitis
Changes to 4.14.4 Vaccines and 4.14.12 Variations from product information.
4.14.4 Vaccines and 4.14.12 Variations from product information
Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also to Chapters, 4.2 Diphtheria, 4.3 Haemophilus influenzae type b, 4.12 Pertussis and 4.19 Tetanus).
Rotavirus
Changes to 4.17.6 Dosage and administration
Amendment of text relating to the need for a third dose of vaccine.
Rubella
Changes to 4.18.4 Vaccines; 4.18.5 Transport, storage and handling; and 4.18.11 Adverse events
4.18.4 Vaccines
Amendment of text to align with new product information. In particular the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.9 Measles, 4.11 Mumps, 4.21 Typhoid, 4.22 Varicella and Appendices 3 & 4).
Correction of text due to incorrect nomenclature (Refer also Chapter, 4.9 Measles, 4.11 Mumps and 4.22 Varicella).
4.18.5 Transport, storage and handling
Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.9 Measles and 4.11 Mumps).
4.18.11 Adverse events
Addition of text on egg allergy to Adverse Events to be consistent with other chapters (Refer also Chapters, 4.9 Measles, 4.11 Mumps, 4.18 Rubella and 4.22 Varicella).
Tetanus
Changes to 4.19.4 Vaccines and 4.19.12 Variations from product information
Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also Chapters, 4.2 Diphtheria, 4.3 Haemophilus influenzae type b, 4.12 Pertussis and 4.14 Polio).
Tuberculosis
Changes to 4.20.10 Precautions
4.20.10 Precautions
Addition of text to clarify when BCG vaccination should be deferred in people with skin conditions.
Typhoid fever
Changes to 4.21.4 Vaccines
4.21.4 Vaccines
Amendment of text to align with new product information. In particular the source of animal derived gelatin was updated to specify bovine gelatin. (Refer also Chapters, 4.9 Measles, 4.11 Mumps, 4.18 Rubella, 4.22 Varicella and Appendices 3 & 4).
Varicella (chickenpox)
Changes to 4.22.4 Vaccines; 4.22.11 Adverse events; and 4.22.12 Public health management of varicella.
4.22.4 Vaccines
Amendment of text to align with new product information. In particular the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.9 Measles, 4.11 Mumps, 4.18 Rubella, 4.21 Typhoid and Appendices 3 & 4).
Correction of text due to incorrect nomenclature (Refer also Chapters, 4.9 Measles, 4.11 Mumps and 4.18 Rubella).
4.22.11 Adverse events
Addition of text on egg allergy to Adverse Events to be consistent with other chapters. (Refer also Chapters, 4.9 Measles, 4.11 Mumps and 4.18 Rubella).
4.22.12 Public health management of varicella
Addition of text to section regarding giving neonates zoster immunoglobulin (ZIG) to clarify it is after primary varicella-zoster virus (VZV) infection of the mother.
Zoster (herpes zoster)
Changes to 4.24.7 Recommendations, 4.24.9 Contraindications, 4.24.10 Precautions, and 4.24.11 Adverse events
4.24.7 Recommendations
Addition of text reiterating importance of obtaining a medical history in patients prior to vaccination, to reiterate the contraindications regarding use of Zostavax in immunocompromised people and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these people.
4.24.9 Contraindications
Addition of text and table to reiterate the contraindications regarding use of Zostavax in immunocompromised people and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these people.
4.24.10 Precautions
Addition of text providing more specific detail of CD4 levels at which a person infected with HIV can receive Zostavax. (Refer also Chapter 3.3 Groups with special vaccination requirements).
4.24.11 Adverse events
Addition of text providing details of select serious outcomes where immunocompromised people have received Zostavax.